Эффективность ронколейкина в комплексной терапии врожденных пневмоний у недоношенных детей

Two similar groups of premature infants with gestation period of 32-36 weeks suffering from congenital pneumonia of bacterial genesis have been under study. All the patients received antibiotics as base therapy. Besides that, infants in the main groups received Roncoleukin 100000 units intravenous through dropper once a day two times with the interval of 48 hours. Leukocyte concentration in premature infants in spite of congenital pneumonia insignificantly exceeded that of healthy infants with the same gestation period. At same time concentration of CD3+ significantly decreased mainly owing to the decrease in CD4+ level (p + and lymphocytes expressing CD69+ activation antigen exceeded figures by more than twice. On the 5th day of therapy the increase (p +, CD 16+, CD69+ and bacterial activity of phagocytes in comparison with infants receiving traditional therapy were observed. By the end of active therapy in the main group concentrations of IgM and CD4+ were higher and concentrations of CD16+ and CD69+ corresponded the norm. Thus, addition of recombinant IL-2 Roncoleukin to congenital pneumonia treatment leads to adequate activation of immune system and to faster elimination of the antigen. (Med. lmmunol, 2001, vol. 3, N 1, pp 95-98)